<SEC-DOCUMENT>0001387131-12-001969.txt : 20120621
<SEC-HEADER>0001387131-12-001969.hdr.sgml : 20120621
<ACCEPTANCE-DATETIME>20120621124335
ACCESSION NUMBER:		0001387131-12-001969
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120621
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120621
DATE AS OF CHANGE:		20120621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-16731
		FILM NUMBER:		12919007

	BUSINESS ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		516-961-1911

	MAIL ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>thera-8k_062112.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 12pt/9.6pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported): <B><U>June 21, 2012</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 21pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>THERAPEUTICSMD,
INC.</U></B></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; font: bold 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><b>Nevada</b></FONT></TD>
    <TD STYLE="width: 33%; font: bold 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><b>000-16731</b></FONT></TD>
    <TD STYLE="width: 33%; font: bold 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><b>87-0233535</b></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State
        or other jurisdiction of incorporation)</FONT></P>
        <P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 9.5pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission
    File Number)</FONT></TD>
    <TD STYLE="font: 9.5pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>951
Broken Sound Parkway NW, Suite 320, Boca Raton, FL 33487</U></B></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices and Zip Code)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>(561)
961-1911 </U></B></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>N/A</U></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Former
Name and Address of Registrant)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; font-variant: normal"><B>TABLE
OF CONTENTS &nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; font-variant: normal"><B><U>Page</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 11pt"><B><U>Section 7 &ndash; Regulation
FD</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom; text-align: center">
    <TH STYLE="text-align: left; vertical-align: top"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">Item
    7.01</FONT></TH>
    <TH STYLE="text-align: left; vertical-align: top"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">Regulation
    FD Disclosure</FONT></TH>
    <TH STYLE="text-align: right"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">3</FONT></TH></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 12%"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 78%"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0; text-align: justify"><B><U>Section
9 &ndash; Financial Statements and Exhibits</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 12%"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">Item 9.01</FONT></TD>
    <TD STYLE="width: 78%"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">(d) Exhibits</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; font-variant: small-caps">3</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 42pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0"><FONT STYLE="font: 11pt Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Section
7 &ndash; Regulation FD</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif"><B>ITEM
7.01&#9;REGULATION FD DISCLOSURE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">On
June 21, 2012, TherapeuticsMD&trade;, Inc., parent company of vitaMedMD&trade;, LLC (&quot;vitaMedMD&trade;&quot;) (&quot;Therapeutics&trade;&quot;
or the &quot;Company&quot;), filed additional patent applications concerning its proprietary formulation technologies for its
products TX12001HR, TX12002HR AND TX12003HR. Two prior patent applications were filed by the Company within the last year. The
Company expects to begin clinical trials in the near future for these prescription products for hormone replacement therapy in
menopausal women. Thereafter, the Company intends to seek FDA approval under a New Drug Approval for these products as early as
2013 and as late as 2015.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">The
information in this Item 7.01 of this Form 8-K (the &quot;Report&quot;) is being furnished and shall be deemed &quot;filed&quot;
for the purposes of Section 18 of the Securities Exchange Act of 1934 (the &quot;Act&quot;), or otherwise subject to the liabilities
of that section. The information in this Item 7.01 of this Report also shall not be deemed to be incorporated by reference into
any filing under the Act except to the extent that we specifically incorporate it by reference.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Section
9 &ndash; Financial Statements and Exhibits</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 11pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 11pt Times New Roman, Times, Serif"><B>ITEM
9.01&#9;FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 11pt Times New Roman, Times, Serif; font-variant: normal">(d)&#9;Exhibits:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Exh.
    No.</FONT></TD>
    <TD STYLE="width: 23%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Date</FONT></TD>
    <TD STYLE="width: 66%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">99.0</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">June
    21, 2012</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Press
    Release regarding filing of patents*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">*
Filed herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 11pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Date:
    <FONT STYLE="color: black"><U>June 21, 2012</U></FONT></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt"><B>THERAPEUTICSMD,
    INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">By:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">/s/<FONT STYLE="font-family: Times New Roman, Times, Serif">Robert
    G. Finizio</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font-size: 11pt"></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">Robert
    G. Finizio, Chief Executive Officer</FONT>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 11pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left">June 21, 2012</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right">SYMBOL: TXMD</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right">TRADED: OTCQB</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>THERAPEUTICSMD, INC.
FILES FOR TWO ADDITIONAL PATENTS</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ON PRESCRIPTION PRODUCTS FOR TREATMENT OF</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MENOPAUSAL SYMPTOMS &amp; RELATED CONDITIONS</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR IMMEDIATE RELEASE &ndash; June 21, 2012
&ndash; Boca Raton, FL &ndash; TherapeuticsMD&trade;, Inc. [OTCQB: TXMD], parent company of vitaMedMD<SUP>&reg;</SUP>, LLC (&quot;vitaMedMD&quot;),
a specialty pharmaceutical company (&quot;TherapeuticsMD&quot; or the &quot;Company&quot;), announced today that the Company has
filed additional patent applications concerning its proprietary formulation technologies for its products TX12001HR, TX12002HR
and TX12003HR. Two prior patent applications were filed by the Company within the last year. The Company expects to begin clinical
trials in the near future for these prescription products for hormone replacement therapy in menopausal women. Thereafter, the
Company intends to seek FDA approval under a New Drug Approval (&quot;NDA&quot;) for these products as early as 2013 and as late
as 2015.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Robert Finizio, the Company's Chief Executive
Officer, stated, &quot;The submission of these patents marks a new platform for Therapeutics&rsquo; expansion in the women&rsquo;s
health market. We envision providing women&rsquo;s health products that deliver a more efficacious outcome while using a minimal
required dose.&quot;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>About TherapeuticsMD</U></B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD&nbsp;is a specialty pharmaceutical
company focused on creating safe and effective therapies exclusively for women. The Company&rsquo;s branded OTC and pharmaceutical
products are designed to improve the health and well-being of women from pregnancy through menopause.&nbsp; vitaMedMD provides
dietary supplements and healthcare products focused on improving women&rsquo;s health, wellness, and quality of life. Questions
may be directed to Daniel A. Cartwright, the Company's Chief Financial Officer, at (561) 961-1911. More information on TherapeuticsMD
is available on its website at www.therapeuticsmd.com. More information on vitaMedMD and its products are available at www.vitamedmdrx.com
and www.vitamedmd.com.</P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release shall not constitute an
offer to sell or a solicitation of an offer to buy securities of TherapeuticsMD, Inc. Certain statements in this release and other
written or oral statements made by or on behalf of the Company are &ldquo;forward looking statements&rdquo; within the meaning
of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management&rsquo;s
expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning
of these laws. The forward-looking statements are subject to a number of risks and uncertainties including market acceptance of
the Company&rsquo;s services and projects and the Company&rsquo;s continued access to capital and other risks and uncertainties.
The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties.
These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes
no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information
or otherwise. </I></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: center"># # #</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"\!
M5@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[V]9UG3]`TG4=<U6;[-IFDV%YJ>H7)4O\`9[&PMY;NZG*)EW$5
MO#)(516=@N$5CQ7Y/R?\%V/^"5:.R/\`M8>&%=&*.K>$_B""KJ2&!SX2.2".
MH)!Z@D<U^LNNZ#IGB/1M5T#5X&N-+UK3KW2M0@2::!IK+4+:6SNHEF@>.:%G
M@GD598G22-B'C=752/Q6N?\`@W6_X),S2R7$G[/7B9Y9I6DD)^./QN.YY&+N
M3_Q7XP"2>%X&<``#CU\JCD#]K_;<LTIQ@DL,LKC0D^16<E5=:K2MMHH\WFSY
MW.GQ0GAUP]#)6N7_`&N6:U,9%NI>*C[*.$@V^K;G425[<K>IZ#_P_:_X)4_]
M'9>%_P#PE/B!_P#,C6WX:_X+<?\`!,+QAXBT+PEX<_:D\-ZIX@\4:QIGA[0]
M-B\+^/(Y=0U?6;V#3M-LHY)O"T,*/=7EQ#`CRRI&K.&=E4$C^33]GW_@GE^R
MAX[_`."[?QF_8C\3_#S4+_\`9P\(:C\3;?0/!*>-O&MG?6<7ASP?I.K:0K^+
M;/7H/%MU]FO[N>9C=:U,9PPBG,D2J@_J)\)_\&_O_!+'P)XK\,>-O#/P!\16
M/B+PAX@T?Q1H-Z_QI^,]Y'::SH.HV^J:7<R6MWX[FM;J*"]M8))+:ZAFMKA5
M:&>*2)W5OJLYR;@W*'AZ53$<1U*^,RZEC\,DL+*ER8B*=&%=NO&2=U^]45)*
M+?+*3/BLCS[CW/%B:M&APO"A@LRJ9;B>>69JK*="HH5IT(N=2G*+C=T_:N-W
M92@E<]*^.?\`P5B^`GP"_;=^%?[!_BWP5\4]5^*7Q<'@'^P?$6@Z5X5F\"V#
M?$76=3T31O[6O;SQ;IVO0&UNM*GEU$6^A792UEMY8!=2.T,?ZN+T'T'KZ>_/
MY\U_$S_P4^GL]+_X.-OV+[V[FM[/3].MOV8+V]O;J9+>UL[.W\?>-9Y+BXGE
M9(888(T>2665E2.&-F9@B<?LK\6?^#B'_@F=\)O&UWX%?XL>*/B%?:5?2:;K
M6M?#3P%K/B'PIIEU`[03$>(;P:19:U;I<;$%]X6;7].<.I2]8>8T7FXWABM/
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MWT[7-2MF<"2WO=)T&^L[N-HY+26>.6/?^L?[-O[5WP#_`&M_`"?$W]GSXH>&
MOB;X.:<6D^HZ)-/#>Z7?>3%.^F>(-$U.UT[6O#^JQPS0S2:;K&G6=VL4\4OE
MF*6-F[,5E&:X*DJV,R[%X:D[+VE:C*$$Y)-)SE:*;3NDW?R//P/$.29G6^KX
M#,\)BJ[4I*E2JJ4I1C+EE*/1I2TT=_*VI]'45\"?M!?\%(_V4_V8_CO\+OV;
M_C%\1M1\,_%SXRR>&E^'WAJR\">-O$L&L_\`"7>)W\&:#YNN^'_#FI:)I:W.
MOHT4S:IJ%JMM%^_FDCME:0>+_M1?\%H/V!OV1O'$OPM^*7QH.H_$NVNH;'5/
M!?P]\+:YX]U3P]<O.D#Q>([_`$*RD\.Z)?1,X,VD:GK-IK,0(9M+`$@BSH9;
MF6)=)8?+\9656BZ\)4Z$Y1=*-^::=M8PM[S5TKJS=]-,1GF481U8XK,<)AY4
M:WL*D:M>FI*J^7EA92;O/F]U-*]G>UC]8Z*^)_VHO^"A'[(O[&-M:3?M'_'/
MPC\/+W4K!=4TOPU<+J6O>,]2TUI[BU2_T_P7X3T[7O%MY92W5G=VL=Y%HAM6
MNK2Z@$P-M.T/YVZ!_P`'(7_!+C7/$$6@S_%OQOX>MYY$AA\3:_\`"+Q_#X>,
MCOM4S-IFBZMJ]I;,V$:\O-)M[2T!\V]GAC!<;8?)<XQ=%XC"Y9CJ]%?\O*>'
MG*+:=I*+2]YP^TE=HQQ/$N08.NL-BLWP-"L[>Y4KQ32DDXMVO9237+W['[U4
M5Y7\,?BYX!^,W@O0?B/\+/&WA[Q[X#\4V4>H>'?%'A;4+75]*U2UD1LF&XMO
M,"SQ2*\4]O-Y4]O<126US%%<*\*?&?P]_P""JW[$WQ+^(_QO^%V@_&FUT_Q1
M^SCH_B77OC+)XM\->)O!/AKP;I/@_P`46_@W7[N7Q3XJT73-!U-;7Q)=VVG1
MMI.IWJ7AD\ZR%Q%@MR4\+B:WMU2P]><L-)0Q$%1JJI0FY*$85*<HJ<).3LKQ
MLWL[G;5S/+Z$*%6KC<-3I8I-X6K*K!0Q$5%3E*C)OWXQB[RV:['Z045^!^O?
M\'(__!+K1/&3>%8?BI\0->TV.[-G-XXT+X1^,KCPE"ZM$KSJ][8:=XCOK)#(
MY%SI?AN_CN%MY);0SQ-`T_ZX_L__`+3'P4_:B\!V'Q/^`OQ+\.?$_P`":@[6
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M[7G[/W[7?@1?B/\`L[_%;PW\3O"OVC['=7.C_:+35-%O3&DR6'B+P]JT%AKV
M@Z@86\Y;/6-.TZ>6(&YMXIK8%AY5\1_^"C7[+'PG_:F\`?L:>./B)J6E?M`?
M$Q?#C^#_``A%X$\9ZA8ZDGBVXU"ST`S>*=/T"Z\,V'VVZTN\C9;S5('MRBM.
M%1UK%83%RQ&(PL<-7>*PL'4Q&']FU6I4E\524'9J"U3?22:=F=$LSR^%&CB9
M8R@L/B*D:-"O[1.E5K3:2I0DKWFKW:LM-4V?>E%4WDF$)*D>9A1\HSM+$`D?
M(=VP$L!L^;&"!G(^#=4_X*2_LIZ)^V!;?L'ZK\1-1@_:;OY]-MK3P,/`?C=]
M/DDU?P;'X^T__BL(O#\G@]1/X6E74"C:X)(WVVTIBG;RQ%&A7Q"FZ-&=5TH>
MTJ*"YG"G%KGG*VT873D_-6NVC7$XS"X-1>)KTZ,:E6G0IRJ2Y8U*M7^'3@];
MRELE;H^Q]7_$/XM_"GX2V.GZG\4?B+X(^'.G:M>MINE:AXY\6Z!X4L=1OXX3
M<R65E=Z_J&GVUU=I;AIFMH)9)_+1Y!&41F'?Z3J6GZQI>GZMI-Y:ZCI>J6=O
MJ&FZC8W,-Y97]A>1+<6=[9W=L\MO<VMW;R1W%O<02/%-#(DD;LK`G^(O_@YM
M_;._9_\`C%IOP_\`V7_A]XPN]8^-/P!^-.O3?%+PS)X4\4Z;::##J7@-8;"6
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M]/OM22[ATW,EHBP:C:B!Y%(N)9/)CS)A3]<?#KQSX?\`B?X$\%?$CPK-<7/A
M?Q[X5\/^,O#<UW;/9W4FB>)=)M-9TN6XM)"9+6>2QO('EMW)>&0M&WS*:_)O
M_@KM>?\`!,>V\"_!C5?^"G%I>W_A"/Q9XFM/A4VGVGQ:NY8?$=YI&F7>OK)%
M\)(9;](VTZPLSOUA?LS)!BSWW;^1/^G7PA'@33/@W\+H?A8!:_#:S^'G@Z+X
M?Q2M?*;?P-#X?TQ/#2RKK3_VH@BT,62RG4R=10`FZ!NMX/CXFAAHY5E^)IX7
M,(8FI6Q#K5ZB<<)64*DJ*AAXJ\ZDJ48_O8N*5XOEOU]K"XO%5<]S/!U<7EU3
M"T*.'=#"T[RQN';A"K*>*<E&G"G5E)RHRC.7NRCS*-FE[!17XO?M"_\`!>W_
M`()N_LY>*M3\#:]\:K[XA^+=$N19:SI'PB\'ZSXZ@TNY$ACDAN_%%O#I_@J:
M[BD!CFT_3_$=UJ%NT<BSVBN4%>W_`+('_!6S]AO]MK7/^$0^"7QJL;CX@+')
M,?AUXUT/6?`7C*XBC\]F.D:?XDLK*R\2F**WFFNE\*ZGKIL(HW^WFVECE1:G
MDF<T\.L54RG'T\.X*K[66'FHJC)755NSM!J[3ZKU1I3XDR"MBG@J>;X">)4W
M2=-8B%_:II.DG>SJ)NUKVOU/TRHKP_XX?M`_"C]G#X>:[\5OC9\0/#_PX^'_
M`(=\L:IXD\17"PVL<MQA;6RM+>%9K[4M2NY/DLM-TRVO]1O')6"REVL5_(C2
M?^#C[_@EO?\`B8Z#>?&#QQH^G"9X$\7:G\'?B)%X8E(D""8"VT&[\200;B?W
MU]X=LU5%,TR1P%9VRP>5YGF%*=?`Y?B\51IM)U:-)RB]N:VSO"]I)I-.RZHU
MQV>Y1E=6%',<PPN"JSC&2IUZU.,K2:46U&4K*5[Q>S5WT=OWCE<1QNY&0JDX
MXY]AD@9^IQ7RSX;_`&P?V<_%7QFUG]GW0OB7I-W\6M"O-8L-0\'26NJ6E['?
M:"L<NKV4%Q>6,&GWMU8PR?:9K:SNYYA:QS70C,,4LB^@_!WX]?"']HGP38?$
M3X)?$GPG\3O!&HR>7;^(?!^K6FK6)F4KYEE=F%C<:=?P[D:XT^^AM;V+<!)&
MA^6OX[?V@?#'Q=G_`&[_`-L#XI_!66]A\6?L_P#C_P`0?%^Y?3Y)7O[;2-,\
M8:)H-[<K$KJ+FRM/[;AN-9LW\R*X\/6VL++!)$DD;^ID>34LPJX^EC)U,)B,
M-0BZ%*JO9N6)G/DA3:G'XKM-[*UK/FT/QGQL\6,R\-L)P?F&2992SVAGF>3P
M>/I4E*O6GE6'PT<7C,1@(TDXU*N'HJI5E&I.FN6$G?1G]O*$%%(P054C!!&"
M`1@C@CT(X-03.J$LW``YX&&`!.&.00!V]_J*^0?V+OVK_#7[6_P.\,_%+0Y[
M:RU-HFT7QGX?$BM-X;\7:9#"-4T^8RXD-M,7CU'3)VS]ITF^L;DDM)*L7!_\
M%"_VQ=+_`&0/@5K/BR.:TOOB#XM@G\,_##P](T;->^)KJ!P^KW,*YDDTCPW;
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MP]^)?@#_`(*<?LP2?&`WS^//B7HGC/XN:R-7E>?6?^*X^%/Q5U"WDUV25I&D
MUNZ6-[_4-[F:TN;ZYT]X[>2&X6;[F_X+#^'M&\2_MD_L*>&==T^#5-#\0:C;
M:+K.G709H=0TS5?B+X:LM0LYV5EE\JZM'DMY=DB'RY90I&]L_4RX=P<,WP6!
MGBJTL/6RZIC*\Z:BZBJ4X-RIQNU%.,H.*?,UL[L_G'!>/O&.:>%_$_&N'R#+
M,NSG*^.LMX4R[+<RI55!83,J^7T:-3,?9N4X5%]?I3J0IN5HJ7*Y-1O^FME_
MP5/_`&"]0NH[1/V@O#4(FVB.:^TOQ+:6REB54SSW.B106\9&'::XDC@1#YCR
MJN<?9?@7XJ_#KXH:)!K_`,-_&OA7QUH,Y"Q:QX4US2]>TXOC<4:[TNZNH%D4
M`[XBXDC;*NJ,"*^.[O\`X);_`+!NIZ9-8R?LX^#;;[6DBO<Z?/KMA>Q&<,KR
MV][;:JLUK*H.4DA9'!``(48'Y)_M.?L6_%7_`()KZO+^UA^Q;XQ\3P_#OP]?
MVW_"Q/ASK<]WJMI8:%/?+:1R:GB6$>*/")GE2*87\$NM>'FN3J<.J2AI[V'@
MIX+),;-8?`8C'4,6YJG16-E!T*E25E9RC*3B[;>Z]>A]OC.,O&7@;#PXAXPX
M>X2XAX7H4XXG.L3PA+,X9SDV"E3=6IC%@\;",<9@\-&+E55&I[6"3DX..W]!
M'Q-^.OP]^$5_X>M/&\OB6*?Q/=&ST-=!\#>,_%RW%_\`,$L0WA30M92/4IE2
M>6UTZ0I>WEO:7MS:P36]C=RPY#_M.?`V."[N9OB!HT"V7Q3TWX+30SM-%>I\
M4-8U"STO3O!HL'C%Z^JWES>VTL2Q6[VYL&;4FG%A&UR/'?@Q\0_#'[<7P3^!
M/QK\.7IT&'3/%VD>,M6T40KJ%QIWB'PWIVM:+K?A&YG9K4JD=[JCR0WRQ.9[
M,6]R+5$N#Y>3?_L'?#R_UJ'QE/=W`\<VWQ4C^(T.O_9KI+66&#XV1?&&#3[C
M0QJ(T^?7[2R^W^![#QC)LU6S\.ZOJ=G;PKI][/I8\J-+#4)U:&,4J6(I3G3E
M""3;G&5FI<SC;FWNM[WLV?H,,WXFS:G@LZX666YOP_F^&PN88#%5)NA4^I8O
M`4W"7M*:JRQ%52G9PG&BXI.,G>-G]]V[)-&LL7".-PSC/)/<%@>0>02IZ@D'
M-%1VB>3;Q1KPJKA?O'Y<DKG>`<@$`\#!Z`#`!7GI*%XJS2;M=:VO=)ZO;;?N
MC]#@JG)"ZC"7)!SBMHS<8N:V_FOOKT?4OTQ^@^O]#3ZAE/0`]""WT_SZ?C4M
MV3;LDNK=EVU?370T?1=Y12];H_BN_9._Y6C/VB_^PO\`&G_U7V@5_:>W(`]5
M/\S7\5_[)K`_\'1?[1I'1=8^-08^F/A[H!.?\]:_M0++A>>Q_0DU]KQS>.+R
M&^G_`!C65[Z?9U_`_-_#Q_[%Q"E\4>*LQNNJ?M=+KH_)_J?P2_\`!>GX2ZO\
M>O\`@M3\%?@AH&HIH^J_%GX;?L^_#Z#5Y6*QZ9'XM\:^-]'N]2<(6DECT^QN
M+N:2W$)%SE+4F1+B6)OZ:O`/_!$'_@FKX!^%-C\+KC]F'X=^-Q'I,=AK7CSQ
MGI?]J_$?7+V2U%O?:R/&9F@UKP]?7K>;((O"MUHEI9O(JZ?;6T:^6?P:_P""
MFY!_X.0OV)`<$!/V6#@X(S_PL7QEC(/!.5!&>00",&O[4BI*#@]5]ONDD>G0
MC/Z&NO/,SS+!9)P?0PN+Q&#A+*(5D\/4E0G.3Q<[.4Z?+.<%RNT7)Q\MV<?"
M^397F/$7'%?&X+#8N=/B&6'C]9IQK0A3GA*;GR1J*4(3;LG424U9>]H?PK?L
M3?#;6_\`@FA_P<'7'[)7P[\0ZW>?"KXFS:SX7AL]4NY'_M?P#XH^'5S\4_"B
M:Y#''#!>ZIX-UO28],@U5X_/N#97%Q#]DBU74;2X]4_X+U_&CQ7^U+^W]^S_
M`/\`!,[3_B+IGPS^$FD7_@'5/BSK^KZM#I/AR/Q%X[,>KGQ%XIGOIX+26'P%
MX`2/5/#EA?3QPRZKKUP?/CN+C3KBSZ3X[*!_P=3?`A!\J"V\'$#G`(_9Y\9*
MI]3P!GGG`[XKY%_X+E?`7X?^%O\`@LEX(\?_`+2@\4:1^S3^TU9_">Y\4>,?
M#=V=.U#2=)\,^&]`^$_BZYTS4[C3]3A^T>#CH6A:_K5G;V=_=QZ3JBI)ITES
MJ%C*?K<(J6*X@R;&8Q6QM;@QXV-6G1A6KUL;[*45B%2G.G&IB/8N56,'*+DX
M<ZYF?%8YXK!\,YYE^"C&.$P_'<,"Z4ZDU1IX'VUW1J3BW*C0E.$(2G>*@G:]
MFT?T*_#7]B/_`((<_#?X2Z9\*3I7['/C*SAT2#3=8\8^._&'PW\2?$;Q)=+9
MQPR:]?\`C>ZU;^WK36+F5#>P2Z'=:79Z=/*W]B6&E(8EC_`;X%ZGX2_X)3_\
M%LO!'PL_9Q^*EAX__90_:9U3P9X5N++2/&6F^--%L_#GQ.UNX\/:)9:K?Z5?
MW.G2:]\,?'5OY]AJMXD>OQ^$FG6X+6VO337'ZQ^&_P#@V8_X)G^+]`T?Q5X6
M^(OQR\0^'->TVSU;1-<T3XF>%-2TG5=*OX(Y[&^TR^L_!;VUY97-L\<UM/;.
MT<D+HR,00:Y?X:?\$9?^"0GPA_;`^''PR\-_M#?$2;]I?P)?Z#\8_#_PMU#X
MH^&;S4IU\):]97]A%J5E;^#85^T37%O#-+X>&H6_B&;0?-U"VM(M,47R>/A<
MTR&C#-L/4S?B//:.*R[$T\1@<=@$J2KU:;5/$.%6KB'0>'K77M8.G:,>5^ZK
M'O8G*<\JRR:O1R7AG(EA,QPTL/B\'CW2]O3]I&+H1<)QCB_:03DX7JN^O<_,
MW_@YRU;Q-X;_`."AG[,GB+P1>7=AXRT#X+>#]:\)7^GC=J%EXFTSXJ>*+[0+
MRP!5E:]MM4@L[BW5@RF:-<XX-?J[^P?_`,&ZO[,/ASX8^'/B3^VEI&O?'G]H
M3QY9V_C+QY8Z_P"*O$^E^%_"WB'7HDUB[T>U3P_JFB:WK>KZ;J%U*NN:]K>K
MWB:MJ4=R]I8Z?92F!_@__@N[96>I?\%E_P#@G'87T$=Y8WI_9\M;NTE19H+F
MVG_:+NXI8)XI`R2P31DI+&X97C=E8$$@_P!JR*$CVCC"X'_?`],?G].:Y\]S
MO,,NX5X/P&!Q%6@J^5U<15JTI^SG/#5:\J5*G&I&TN6%IN2BUS72?1/LX?X>
MP&9\7<:XW,<-0Q,L'F=&-.C-*="%54(3DW!OEYTXIWDN:)^+7_!27]FG_@E=
MXX\;?#;]HG_@HIXC\,>&F^'OAW5/!/ABQ\4^.;KPQIOC+3)-8?6QIEUX?\.R
M1^,?&4OA^ZFU![+3-+G:*`:QJ4LMC<&X+1_F#\0]:_X-?_C1X/U+X8:3J?P:
M^%VHZE8S:3X=\?\`@SP'\4/A_K^A:M-#+;V&KQ>*?^$6MK*\FM'5)43Q8UYI
M,Z1^1?6\@VQ'X4M/A;X9_P""H7_!?#]H'X1?MB>,M;M?AY\,_$7Q4\/>"_A^
M^NWNBIK>B_"'7+30/"WPWTFXM[FSNM+@UBQDU/QSK<^DS17^H16NM7-AJ-O+
MJ$]U7])WC?\`X(]?\$DM#^'>M77C/]E3X.^&/"/AS0;Z^USQ+=:CXE\-WFFZ
M-86\UU>WNJ>,+3Q+I^LK%:6\+S7%S<:F^P1"<D%$`QG/#<.PRC!XS-^)GC<5
MAJ&*H4,OQ$:>$IPK_O*:BFU*M4O_`!+IW=DELB*<L9Q&\XQV`R3A:E@<'B*V
M$KUL?1<\:YX>T)R<K.%&%K>Q=XJ-KNR=S\1_^#83XI>)/"GQU_;._9"M/&D7
MCGX6>&[2X^(/@K6-,OUOO#L^H>&/'3^`-4\5^&Y8I)8)K#QYI^JZ!JKW%NYM
M[M-(L+R$LLTQ;\O?V>OV(]8_X*`?\%?/VIOV?Y?%>N^$?A8/C'\;?'/QQO?#
ME^]E?:A\._"7Q8E,6CVBR1RVDNI:GXIUGP_;:?)JMAJ=II=S<?VZEK=MID<<
M7WG_`,&UH^'Z?\%)OVVX_A,D\'PJ3X9>/H_AC:W<]W=75K\/H_CSX<3P;;75
MS?SSW]Q/;^&_[,BFGOY9;ZX<?:;R:2YFD>O+_P#@F7^UQ\.OV5O^"W?[7%E\
M6-:L/#/@GXZ?$;XY_">+Q+JUS!8:-H'B^?XPOXB\*76K7TQ2.TL+Z;2+_0%O
MKB2*UMK[6E-S(BJIKZ[$U,53SKC;$9;2Q,\;+(LLKVKTH?675=&C>K.C&-YU
M&KS3E%WE:7Q:OXVC]6Q>2<$4<YDXX"CQ+F.%K5/:2G&%&523A"-6Z_=2;4='
M90OJHG]1Z?\`!%C_`()E#X<_\*S;]D?X52:4VFG3SXG;2)3\2&9XW4ZBWQ*:
M=O'#:D)'$Z7!UWRT95@2!+$?9*_F2^#?A_QO_P`$2?\`@M7X3_9N\.>--:UO
M]FS]HS5O!VCPV&K3,R:WX)^)U]J'AGP->:K;P&WTUO&/PX\=QOI[:I9VL*W>
ME#4(X+'2[3Q-]DL?[IX-5TUK0WJW]JUEY(N_M8N(VM1;-$LJS"X&(C`T169)
MBVV2)A*K%"&K^'?]L_Q_H?\`P44_X+_?LP_#SX"WD/BWPY\"?%GPQT'6?%^A
MM'JNBW4WP>\9:A\6?B9K=OJ4$CVAT;P_'#-X?2YBG\JZUNS,2/<V^I:-+)\=
MP=F6:9E5S?#YE7Q&-RO^Q\QJXY8FM.I1PV)IX=RIS4JC<:=:-2W+9QD]$TTK
M+[_C;+<JRV&2XK*L-A,#FL<WRV&"^HTX4ZV*PT\1%3BU2M*K3E!>^W&48WNW
M=W/6_P#@X,^.GC']H;]L[]G3_@F=X9\>Z;\.OAS?3^`O$GQ6\1:WJJZ3X;'B
MGQUJUZ-,O?%]U)<6MO+H7P]\&VJ^+X!J-T+:XO\`7IY]B:CIFER2_K'\)/V'
M/^"('PG^$MG\)EM_V.O'EN-'73-<\:_$;Q=\,/%7Q#\278C<-K5[XOO=174M
M/U(73O?V8T,Z99Z-=,6T.TTY(X%@_`3_`(+\_`CP7X0_X*R?!WXG?'^V\5P?
MLS?'WP[\,6\8^)?"LKV.J:78>%+J;P5X_M-(O[FUU")=:\-Z/9^&_%3VLELT
M,MIJ=G%%#([7#VGZS^%O^#:+_@F/XX\/Z+XL\)_$;XZ>(_"WB'3;75-`\0:+
M\4/!^HZ+K&GW<:RP7^G:E:^#)H;RWN5D4Q2QR^6P4^6N,,>_&5,JP_#G#47F
MN:95AZN%^LU)Y92@H8G,)5?WGUBNY1;JTTHJ-%R7+&3M%7:?@82EG..XGXHG
M#),HSG%4<8J%.GG>-=&>&P<8?N9X3#SP]=2IR7,Y8A0B^9*TWT_)OP)J'@7_
M`(),?\%K?ACX;_9>^*>F^/OV4_VE-8\(^'=5T70/&FG>+](M/#WQ-U[4/"=O
MX5U;4M*OKB&ZU#X9^.KRVUSPK=:B\FK)HK117EW=?:]6DU#Z@_X*!2*?^#EO
M]AXKG:]K^SJP(.>OB?QRN#UY^4GC@J5.<D"OHOPE_P`$6/\`@D'\'_VM?AG\
M*-/_`&@OB''^T;H.H:+\6O!?PRU'XL>$;G6[MO!.M:;K-O%?6(\)0Q;KZ:P6
MZCT*ZD@U>]TFUU;4=-@-EID]\GQW_P`%:_&VD?`'_@X!_8Q^,WQ'DDT3X>:5
MH7[//B"_\0W2-#I]KX<L?B3\0-#U[4GNVC*HFAWD,MY?;)E%M:-$9_)M;J(R
M=]'&X#-,RISP2Q5?'0X0S/`XC$5\,\/B<=6C&I6HU'3A%+$5'2:3DHR<VN:[
ML<E?"9IE>33>81P=+"2XRR^KA\+A,9'&4L')RI*M%5;N4*;NXQC+E6J]R+>G
M]MJ@LNX''*,0>>#@XS],#/>OXJ_BF0W_``=@>$^,G^W/AUUYX_X9`T]/IRS;
MB?;FO[.8O$&B7.BP:Y8ZQIMUHMQ8P:G;ZO;7UM-ID^G2PI<P7\5_$[VLMA+`
MRS+=QR-"\+;HY#D&OX8_#WQP\"_M"_\`!T'X3^)?PSU>V\1>#&^)Z^#M-\0:
M?<P7NE:Y-\._V>+[P+JNIZ/?6Q-O?:3/K/AZ]-A>V\LUO=0*DT$\L+(U?*\%
M4*DI\2U8+W,/PWF<*[=G&$YJD_9RYKJ%1R6FTHVLK:'VGB#B,.UPM!U/>K<3
MY34A&-G[14HMJ22TG"+DU)*\;VO?0]M_X.AOV6/@%\*_!OPA^/\`X&^&NA^'
MOB_\8OC3X@A^)7C>REU)]3\70V?@>6>U34H;F^GTZ+R9[6SF4Z?96;$P%9"X
M*[?V?_9&_P""0W_!.6]^!G[-'Q9NOV6?`5Q\1;KX5?![X@W'BJ:^\6M?R^,Y
M_"?AWQ')K[0GQ']C-T=;8W_E?9_LWF?NS"8ODK\Y?^#L5'E_9I_96E5':*+X
MX^)H9I-K>5%*_@&_*1R2$!$9_)E*!B-XBD*Y"/C^B[]C'6=(OOV0/V7;VSU*
MQNK*7]GGX-M'=6]S%+;,L?P\\.0RD3(QB_=2JT4OS?NY5:-]KHRCKS/,\QCP
M-PK;,L="=3&YY1J\N*JQ=2C2K451I32E[U*FFXTX/W8JZBDCFRK*<JJ>('%-
M*MEV"DJ6`R7$TXU,/2;AB)PYZE:'-&ZG.=I5)K6<E>3;/YOO^#LF`P?L]?LD
MAB&/_"X_'`W#/('@6/));)W,2Q(R0,@*``08_P#@M1^V]X]_9U_X)N_L<_L^
M?"/6;_0/'?[3'PD\$V&OZYH]S/:ZOIOPU\-^`?"B:QINF7%FZ7=O?>+]8UC3
M=$,D*R/+HMKXDL=@%X9&M_\`!VA(DG[/?[))1@V/C)XY)X(QGP+'C@@=<'\J
M^3?^"_WP>\91_LM_\$QOVH?#-B][HGPY^%/A#P#XDNQ;_:[/0=4UCPGX,\5>
M#;S4X&$L4=IJ=YHNM6+7<R1VRS00V=T7>_L`GT'#M'#XO`<!T,7RSC_:>?2I
MPJ6<:N(C3JU</3J2?25;E2B]'IHTSYOB>O5H9QXAU,$^2:RG(85JE"7).AAZ
MD\/'$U(1IZZ4I2<I)+E2T>FG[`?\$[O^""_[('P%^!_A.\_:#^#G@?XZ?'?Q
M1HEEJGQ!U+XFZ'9>,O#GA[4]2MH+BX\*^$_#6KK=^'K.TT(;-.EUW['=ZUK%
MW%?WC:LNGWMM86='XX?\&[?[)OC7]H+X/_'/X&:IX@_9B@\'>.+'Q)\0?!OP
MINKC3-*\0Z?I1_M'3SX#D>62;X9ZZ=8LM.@NKG0,Z8='ENUTW2M,U:WL-4A_
M6C]C?]K3X1_MC?`#P-\=?A3K^FWND>)](M+C6]#@U""[U?P7XDB@2/7?"?B.
MUC;[3I^K:+J2W%HT5U!;_:K5(-2M8S8W=M(UGX\?MG?LR?LT>(?AIX4^.'QF
M\&?#CQ!\6_$B>&?`VG:_J207.J7SQ._VV[V;X]$T!)?(M9?$.LFQT"VO[NPL
M;K4H9[Z!)/@JF=\41S7%QEC<P>-MB*-3!*52HH8>,I)Q^JVDE3C!:/V?+!7:
M:NV?H.%X>X0EDV!G/"9:L(EAJM/'N=.E.IB>6$N:6,4U.5253XHNHW)NTHW1
M_+U_P=/)XTT^_P#V);/Q!#XCOOV<[35O%TGBRVT:YE$MYXRBGT%6AFN;TS6:
MZ[)X,.K+X=NM1<W1#:ZUM))&NL>9]U_LZ_"S_@WW_;6^%OA[X>?"7X>_LP2W
M=UI4$$7A*\AL/`7[0NF7DL<,4@O=4O;K2OB7?ZRL[6HGUBVUO6;;4;F)XFU#
M5/)P?U[_`&B/$?[&_CVY\-_LR?M,:U\'/$%W\;M+OM1\(_"KXF7NARW'C>WT
M<V:R7FAZ?JTL3MJ5I)=VS:7<61MM2:X$ITB1Y+2Y,/X-_MA_\&TO[(6K>$O%
M_P`0/V9/'WB_]G#Q9H>D:QXDTK1]9\1S>-OA?#<:38W.JI;3ZAXHN9_%WAVQ
MN3;[3KB^)]2705D>\BTB_BA.G3^WE>;9=B<KRS*LQQF;Y#BL-5QCP&9X"'+A
M\34Q6(A[F,IRY)S2G>*J4N9K9/ENEX&<9'C:&<9QG678').)<)B:&%AC<MQS
MB\3@:6$P[O5P]2;DD^5:QBTI/[+E:W[>_L+_`+`?P&_X)_\`POU?X8_`2TUC
M^QO$GB_5?&NMZSXKOK;5_%&JZAJ$LD=C97VJV5EI<5U8>'=*^SZ'HD36B20V
M,,DMRUS?7VHW%U^8'[#NGV>K?\%;?V_M.OK:&ZM-0T'X@VEU;W$:S6\]E=?$
MCP.+JUFAD#)+%<*T:RHX972,QGY)&%>7?\&T?[8'QU_:!^"WQY^#WQG\3ZKX
M\M/V<?$WP_TGP%XQUR\EU359?#OC>S\9,_A:YURX9K[7+7PO<>"Q-IMWJ-Q?
M:A'8>(+>R69-)LM/M;'US]@PA?\`@KU^WB6.`-)\=`Y]3\2/`0'UY('&:PE@
M<9E^)XMPN/KO$8NA@\-.5?FYWSRJPE"I"=W:7LW"5XM6;[GYSQKBL%FF=?1\
MJ8##>PP&)XYS*FL''F<)..18ZG5H3@VW.$X.NI4VG&I3C=IJ":\EUA-1_P""
M0?[<!U>"&];]CS]H>?[-/%;6]U<6GA*Y%SYK11A&#/JO@>Z1KBSC0S7&H>#]
M6OH[:*\U725C@W_V??#>O_\`!4[]M#6/VEOB#9W47[,?P%U:WTSX6>$]6MIQ
M9^(-3@N8+^QMI+61Y+6:62\L;/Q;XP1@1ONO#VB*L]F@:']N/VL_V7O!7[6?
MP7\3?"+QA&UDFIK'J/AOQ+;6J7>H>$_$]D)#I/B'3X'FMQ-+9O*Z3VHN+<7U
MC/>6+3VXN3.G7?`'X%^"OV=_A-X.^$G@;3S9:%X.TM+-9953[9J]](3<:IK>
MHNAV27^KZE+=ZC<N%10]SY:1PQQI#'Q3SVC+"1KN'+G,L-'!5<5'5RH<KM4<
MEI[6S455^-MV;2WPPO@CG5+B]9)4S&@_!7"YF^,,!PY&565>KGM5\T<EJTHR
MM#)\+B(QQ5/#M^Q<Y1BJ;NT?B;\3H([?_@O5\!(XE6-%^'<XVKD(?+^#?Q9B
M!`8EATPJL7"`%E(>>4M4_P""M;?\9S_\$_<C@>)=%(Y^\/\`A9WACGCIG!J]
M\5BB_P#!>SX#L7`5?AY/U(&0WPB^+B\9Y)RN2%!(&6("HQ'U!^WC^QE\9?VB
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M>6%!.'.U43D*<G@97;OYP&')&<5^-O\`P5(_;W\(_"3X7^*?@+\-/$-EXN^.
M_P`5+"Z\&V^@^&[F'5+OPCI>O%M.O[[68K`W,D&J75A<36/A_2%:VU6ZO[B.
M\5!:VS%OD\NPF)QV/P\,+&3MC*5652*;C3I0G"4JCDDURJ*:;\[ON?U!X@<3
M9/PEP;G&8Y[B:$(4\FKX2GA7**Q>8XC$X"K0I8+!4N:,J]3$59QI>SA&3DWR
MV;/&/^"`.NZI=_`+XT:#+Y@T71_BQ8W^ER2[VB2YU?PAHXU6TCSP`L>EV5S+
M&I&V>^E=@6E!/]`BAG)#$$#'8]0/J>.>GN>W%?G-_P`$N_V7M5_9>_95\/>&
M/%=F;7QUXVU6]^(/C?3V.Y],UC7++3K.RT:5Q@//I.@:9I%C?[%2)=2BOA$F
MPAG_`$<B5@26&.3_`$Q_GUK7/<53KYKC*M%J<9UVE427O6Y8-W2L]8OY'C^!
M^39ED'A9P5EF:T*F&QU/**=6MAZR2KX6&(<L31P]2R7).E3KPA*.CBXN+2::
M2^6W<C]1_C14M%>3=^7W+_(_65[J26MN_O/YMW855F(#''4`[O\`=V@].I/?
M_$\5:I,#T'/!X'(]*EJ^CVTNN]G?\TB9*Z5G9IQ::W5FF_O5U\[GX-?![_@D
MKXP^%_\`P5B^*'_!1ZX^,WAO6?#'C^^\>7%O\,K?PCJEMK6G-XN\.:;X?B6?
MQ))K$MC<+97&GR3NT6E*)TD1%,;!C7[KE_W6["@A5Y_ARPYP3C`ZX)([%L#-
M7#'&>J(>_*J>0<@\CL0#]12E5(P54CT(&/RQ77CL;BLQG2GBZKJ2H86&$HNV
ML:5.5Z:U_ECH>;EN3X+*HUZ>#A*%/%8ZOC\0I2YI3K5[N3YK+[3NG;HEYGX,
M_M3?\$D?&G[1/_!3OX%?M_:;\9/#7AG0/@W_`,*D6_\`AO?>%-4U#6=;7X;>
M(]:\03M;:[!JUM::>=5AUA(;=)=-NC;R1?,9%8,/WB.1&H.`<D=<@-AOH2,\
M<8/.:D$:#HB#Z*!WSZ>O/UYIV!C&!CT[?E3Q6.Q.,C@Z=>?-3P%'ZMA8?\^Z
M"?/R?^!N4NNY6`RG!Y;5QU;"P<*F8XCZUBY-W]I7Y>3GVT;BDK:[+T/PN^(W
M_!*'QGXP_P""N_P^_P""D\/Q?\-67A?P;'HD4_PMG\+ZD^N7O]E_#C6_`C&/
MQ*FK"QA+S:O#J)W:3(B11O#O+D-7W)^W7^P-\!OV_O@Y=?"7XW:1,3:W$FI>
M!_'.BI:VOC#X?>(S:M:KK7A_4YK:Y$<5Q$$@U?29XFTK6+6.."]A5X;.ZL_N
MORT_N)V_A';..W;)QZ9/J:4JIX*@CT(%;U,WS&I6P.)6)G2Q&74*6&PE6D^6
M5.A0BHP@]'=<MXRUU3:.:GP_E<*694*F%A7P^:XEXS%TJOO1GB)*\Y]+7FE*
M-MFNY_&]9?\`!`__`(*E?!I+KX>_LQ?\%0=9\*?!&:><6^B#XE_'?X8W.G6D
M]RV3!X2\$3Z_X9%^]N(TO+NQU/2GOW5EF=8FPOZ1?\$VO^"$WPH_8R^(;?M%
M?&+XB:G^TG^TUF[N=,\<Z_I\EKX<\(ZEJ<+07^N>'M,UB^UW6=0\5SV\EU8R
M>+=?U:XOH[6YN(]-L],EEFN9_P!_MB?W5X)(^4<$\D].I/)/>EVK_='/7@5Z
M6-XMSS,,/4P^(KX>G"O9XCZMA,/AY8BT5"U6I3IQFXM*\HIV<M;'EX'@?(,O
MQE+&TJ.)J5L/)SPL<1BJU>AA)-W3P^'G)TH-/5-IM:+S/P;_`."@'_!)+Q=^
MV/\`MS_LO_M;Z#\9O#G@C1OV?)OAFVI^"M3\(ZEK6I>(E\"?$^3Q]<_8M5M-
M9TZTL&O;24V$0FM;@Q39E9&0%3^[%OF6(,PVL,`CMN*+N`)`..>"0,\5;*(>
MJJ?JH]_;W/YFE`"]`!]`!V`[>P`^@`[5Y&+S'%X["X/"8F494LOH_5L(HJWL
MJ'-SJFM%>TVW?\CW,#E.#R_%9AC,-&4:V9XB.*Q;;NJF(45"4VNTH146O+[O
MYWO^"D7_``0?\._M8_&4?M3_`+./QFU#]FO]I&>73KO6]<LH-13PYXBUO2+=
MH+#Q7%>^'+S3/$GA+Q?#:Q6MO/KNBW5Y:W$5A;3S:,U\;R\O?E#0_P#@A7_P
M4%^.UQI7A?\`;U_X*:_$#XB_!73;N%]2^&W@CQI\2O$[^*K:UN`PCU"]\?)I
M>AZ?J31*$&J:GX8\7:C9R37.V:Z/[Z7^M#:I&"`1Z8&/RZ4A5<'Y5QUQ@8R.
MG'M7JT.*\\P^&HX2&)ISHT(<E&=?#4*^)H1TTH5ZE.4Z:TV322T5CPL3P+P]
MBL95QD\-6ISQ$^;$4L/BJ]##XEW6M:A3FH3EOJUJ]7J?S^_\$QO^"-M__P`$
MY?VH_CW\;[#XLZ!XL^'WQ.\.^)O!O@3X?Z=X>UO3]7\$^&[_`.(.D>*?#%EJ
M6N:KK6KOKDFD:+I%MH5U<+&DT\X%](Y7S,_SX?L4?L)_!?\`X*$?\%*_^"GO
MP3^,W]KV-I9S_&OQ1X,\7>'KB*#Q!X,\7Q?M!Z-IMEKUD+A)K/48DL]1O=/O
MM(OXY;'4M+N[BUD6.YCT^^L?]`:XA\Y,(B')^=3M`;H0Q)1MV-@3!_A8]PN/
MS$_9+_X)7?!#]D']J7XX?M6_#_Q9\2-8\=?'V'Q7!XNT?Q3JNB7?A?3X_%WC
M>Q\>ZA_8EEI^AV%[`]OK%C#!8R76H7;+8S7<<P9_(<>A@N,,32AGF)S',*SS
M;,L+A:&%Q48J,O:8:M!QC>/14(N$G)2BUHU9V/&S'@;"2K\/X/+L%'^R<#C\
M5B,?AYUI<LZ>(HN*;YI.3M)I+E:DK733M?\`!K5O^#?3_@I=::>_PA\)_P#!
M3S7)OV<W$MBWA35/&OQVTJQCT*:57^Q7/PIL?$.I>!K[]RTL=U"NNV]M>/\`
M,T4"WDJ6O[9?\$R?^"1?P#_X)N:)JFH^&;Z]^)7QK\8:=%8>+OC!XEL+*TU%
MM,@E2=_#O@W2X$F7PQX=DNH[:XU&U%_J.IZU-9V$FMZC=P:=I5KI_P"O"JO.
M%'7DX&21CD_D/R%*%4=%4<`<`#A1A1TZ`<#T'`KSL?Q7GF987ZKB,33C1E%.
M4:&&HX7VDN5+FK>PA3]JY+5\[=WJ[GN9?P5P_EN)6,PF'KNJG>F\3BJV*5)7
MORT57<O96>SA:VEK'Q=^VQ^PE\!OV]O@O?\`P9^.^C75WIBS_P!K>%?%.AM9
MV?B_P%XGBM;JUM_$?A34KVSU""VO3;W5Q:WEG?VM]I>J6-Q<V6H6=Q#,/+_F
MOT__`(($_P#!3_X)+>^`?V5/^"G>K>$/@Q?2S^3H?_"P?CK\*[FRMY6!F:#P
MIX&N/$?A_P"WC+B74;#4=*N+M%BA9XE#.?[(L#D8&#U&.OUHVKQ\J\=.!Q]/
M2LLKXBS;)\,\'A*].>&<U-4,5AZ.*I0E>[G3C6A+V<^THVU2O>RMKG'"&2YY
M7^LXRC5IXEPY)8G!XBM@\1**Y>6,ZE&:<X65FI7?9J[/YZ?^"<__``0A^&/[
M(OQ1@_:/^/?Q-U7]IS]I.UOKG4=(\4>(;6=/"GA75;J$V]WXAT^PUR^UO7?$
M'BN1)ITB\4>(-4DFLY'AN-.TK3[RW@O$^O/^"H/_``2U^$'_``4L^''A_0O%
MFKWG@/XI>`WU"Y^'/Q3TFQMM0O-(75C;?VAH'B#2YFB.N>$]4-K%)=V4=Y97
M5G>)%>65[%'+J5GJ7ZL[$'1%Y.3\HY/KTZ^]!1#C**<=,J#CZ<<5E5S[.*V9
M4\VJ8V=3&T)0]A5<84U1IQ7+[.-.DHP<?9^XDXM-7YDTVC;#<+9'A<JJ9-3P
M%-8"NE+$4Y5*M2=7$)QY<3[6I*4XUHJ*<9)W4DGLK/\`C&\)?\&]/_!1N#2E
M^#7BK_@I;J>D_LU;X[2[\%^%_&GQPU/3+K16\E;BUC^%NIZWH?@;3%F@B!DA
M;6=0M4,TSF&[;Y9_L+]G3_@WTTK]EO\`;Z^#W[4WP@^,UC'\(/A+%HXM/AMX
MC\/ZIJ?C;6K^/X83>"_$NN:IXOCU2WT=+_Q-XKO;_P`6F"Q\/6NGVD&H-86M
MK&ELDDG].X1`<A%!ZY"C.3P3T[BC8G/R+SR?E')R3D\>I)^I->C6XRX@KT:F
M&GBJ*PU6C7I5*%+"4*$*SKRYG*O*E",ZC6R<FWU35SR<-X>\.86>&J0I8JM5
MPM>E6H5\5BZV(K453NU3H\\G""N]&H72=M;(_/S_`(**_L$_#G_@HA^SKJ?P
M*\?ZS?>$[JSUNQ\8>`O'&EVUO?WW@[QEI=IJ%C9ZFVFW+)#JFG7-CJNIZ7JV
MFM-9R7>FW]PMK>V%XEM>P_@C^SC_`,$`/VY?A9\1OA;9>+O^"AEW<?L\_"SX
MB^#_`!K;?#'PGK'Q972==M?"OB>R\1+I`\!W^O:=X.\/)J$MH(A,MSKJ6K2W
M,@M;K?F7^O':O/RKSUX'.>N>*-B9!VKD`@':,@'&0#CH=JY^@]!7#E_$6<9=
M@*N68?%IX"K*I4^JUJ%"O"E5K*/MI49U82J4XU&MHR5K)IZV/2S#A+)<RS"C
MFM?#2IX^C[*/ML/7K4?:PH*U%5HPFO:NFKI<]T[ZKJ?C'_P6)_X)B>*O^"FG
MPU^#/@3PM\6/#_PIN/AEXUU[Q7>:EKWA?4?$L&K1:MX>CT5;.W@T_5=+DMI(
M9`;HR2RS)(@\L+&,S+]YWG[,/PY\;?LOZ%^S)\:=$TCXE^!4^%OA7X;^*=-U
M&S>*PUS^P="T[2?[4LHVE-YI5W'=V<>IZ-=6EQ'J>EWT5K<P7GVNWAEC^JB`
M>H!^H'^>PHVJ1@JN,8Q@8QZ8]*XJF9YC5P>!P4ZZ=#+<14Q6`IQ4J:PV(K3<
MZM6,X-3E*3E)I2=E)]K)=T,BRZ..QN/="-2MF>'HX3'\Z4HUJ&'IPIT8<K5O
M=4%?F33WWU/X\O&G_!N)^U#\$O&WB#Q%_P`$[?V]/%'P9\.Z\\RS:'XB\9?$
M7X;^)K2RED:5;"[\<_"".<^)H+4*L$#7OA?3YA;01(\K>6V_W#]E#_@W-@MO
MB_IWQZ_X*%?M#ZQ^UCXXTJZL]3A\(RWGB;5_#&JZE9,)+?\`X3GQ7XYOKWQ1
MXXTR*0R3+HK6&@Z?/'(EIJ2ZC9?;8=2_J;$<:X"HB@8P`JC&!@8P.PX'H..E
M."J.`J@<\``=3D_F>3[U[E3C3B&IA981XNE"G.G&G*K#"8>.+G"*LX5,4H*M
M*,EO[U]7KU/"I\`<-T\5#%_5:TYTZOMJ5&IBL1+!TYZ>]'"<_L>967*^5)=C
M\3/^"E7_``14^!?_``4)U;0?B.?&_C+X._'+PAX;TSPEX7\<>'KD:KX<3PYH
MMQ=W>C^']4\&7<]M!!IFG7%]J$UD_A:_\/7D,U[=O/+="=U/Y1WW_!!;_@J7
MK>CR_"#Q7_P56\3:O\!KR/\`LZ^T*]\;_'768Y]#41P)8S_#[4?$;:!=6/EN
M5719O$KZ()O*DDM'$0!_L.V)G.U<Y!SM&<CH>G4=O2EVK_='Y"L,%Q7GV`P]
M/"T,72E0I1G[*-?"86N\.YRC)>PE4I2E!1L^5M\RNG=.]^C,.".'\RQ4L;B,
M-7AB*EU6EA\9B:$,0FTVJT*<XQDI/XHI*+3LDD?GY_P3V_X)\_!__@G5\"(?
M@[\*;O5->NM4U9_$_CSQSKRVD6M>-O$TT,-LU[<Q6,*V]AI5A;1)8Z!I,(F_
ML[3XXUN;W4=1GU/5M2X3]GS]A[Q#\%?VTOVAOVHK[Q_I&OZ1\:K+Q!:V/A&U
MT2]L=1T+^V?%'AO7TEN=1EOKF"_$$6B7$+B.UM=TDL#`D%POZ>[5QMVKM`P!
M@8`QC&,8QCC'I2&*(D$QQDCH2BDCIT...@_(>E>5+,L=.>.J3KRJU<PCR8FK
M4UE5CH_?Z736BC:,4DDNSS#@KA[,L1POB,1@E&?!V/EFF01HU)THX3&SPU3"
M2G)1?[V#HUJRDIW;E.[81XV)M.1L7!'((P,$'GJ/>H)A\^<,>,9!P.0>O!X]
M_P#)M4F!Z#\JX;>ZX]X\M_NUMUVV/J^6+23BFE;1W5K:IJSZ-+KL?B;^V)_P
M3+^+G[0O[3L?[1_PM_:*3X+Z[8^$=&\/:1=Z5I?B&'Q5I,]C;:S8W][IGB70
M/$NAWED-1L-8GL)C;")Y+"XO;21_+N&KR)/^"8G_``4#!"M_P4Y^*N\?)O/B
MOXQ[SZ;L?$OEF^\26RS'<QW$FOZ#MB?W%_[Y'O[>Y_,^M&Q.FU<'J-HY_2O=
MH\19E2I4Z+>&J0H0A3H^TPU*I*,(I+E<IQDVM-MMC\7S'P$X!S+,LQS:4.(,
M'C<UQ\LTQ_\`9?%&?Y7A\5CZB49UZN&P&/H4&W#W5)4U-Z.4FT?SY3?\$J?V
MV==4Z9XW_P""E7Q:U/P[=#9J-C_:_P`4]2%W`3MDA:'4OB@]EM*,P(GMYT8X
M!3`.?LC]E'_@E9^SI^S#KEO\09GUGXL_%&(F[A\;?$&/3[PZ7?2JR37V@:(E
MF;73;UQ)(/[3O)M4UR%9IXX=6B@GD@K]1=B'&57C@?*.!QP./8?D*"JD8*J1
MC'('3T^GM66+SS,L73]DZT</3EI/ZK2I4)-=5%P@FKK1IMJW2^IUY%X&^'60
M8^AFU')JF9YG@ZCKX+%\09EFN>U<)75O9U*4LTQN*C^[:O%^S4XNSC)-%:T&
M$D`!P)"`<``@*O*G<V1[EB3W)/-6Z1551A0%'H``/TI:\EN[;_R^_32[W?F?
;KD4U%)[I*_O2GKUM*?O-7VOLM-D%%%%(H__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
